Research and Development System of Shijiazhuang Pharmaceutical Group Co., Ltd.

Unacon pays more and more attention to the development of science and technology while implementing strong alliance, expanding production scale and improving enterprise competitiveness, improving the scientific and technological content of enterprise products and increasing the added value of products. Unacon has established a complete three-level R&D system for the group, subsidiaries and workshops as a technical platform for the company's development. At the same time, through the establishment of research laboratories with Shenyang Pharmaceutical University, Academy of Military Medical Sciences and other units, through the marriage of schools and enterprises, the advantages complement each other, forming a scientific research and development system of "self-research-oriented, joint development". With the help of the technology and talent advantages of Unocom postdoctoral workstation, accelerate the R&D process of enterprises.

Shijiazhuang pharmaceutical group co., ltd

In the first half of 2004 alone, Unacon invested 654.38 billion yuan in R&D talent introduction, training and R&D funds, which was twice as much as 6543.8+ 0997 at the beginning of the year. Now it has 5,000 square meters of laboratories, 6 pilot workshops and a large number of advanced analytical and testing instruments and experimental equipment such as liquid chromatography-mass spectrometry, gas chromatography, high performance liquid chromatography, infrared chromatography, scanning electron microscope, high performance capillary electrophoresis, atomic absorption spectrophotometer, thermal analyzer, chromatographic system, electrophoresis system, low-temperature refrigerator, low-temperature high-speed centrifuge, freeze dryer and centrifugal granulator, which has created a good hardware environment for the development of new drugs and technologies. The number of R&D technicians in the Technology Center has reached 7 1 person, and a strong R&D team has been established. In recent years, * * * 8 new varieties have obtained clinical approval numbers, 5 products have obtained drug approval numbers, 2 products have obtained new drug certificates, and 140 varieties are under development.

Unacon invested/kloc-0.6 billion yuan in technical progress and innovation, and adopted advanced technologies such as information technology, genetic engineering, enzyme engineering, nano-membrane separation technology and chromatographic purification technology to transform traditional industries, and launched a large number of new technical projects such as semi-synthetic antibiotics, 7-ACA, cephalosporins, vitamin C derivatives and soybean base. Among them, the total production capacity of enzymatic 7-ACA production line is 1.600 tons/year, accounting for more than 32% of the international market share. It is one of the most advanced 7-ACA production lines in the world.

In addition, based on the original cephalosporin products, products such as cefaclor and cefepime were further developed. After successful production expansion and transformation, vitamin C has achieved technological breakthroughs such as two-step fermentation, new resin exchange technology and nano-membrane separation. At the same time, deep-processed products such as sodium vitamin C and calcium vitamin C have been further developed.

Practice has proved that the three-level R&D system has many advantages: it can fully mobilize the enthusiasm of the group to participate in and invest in R&D from subsidiaries, production workshop departments and levels; Effectively solve the problem that technological innovation is out of touch with production and marketing; Make the research and development work meet the needs of the group's short, medium and long-term development at the same time; Strengthened the reserve force of the group's R&D talents.